Annual Total Liabilities
$235.21 M
+$70.03 M+42.40%
31 December 2023
Summary:
Madrigal Pharmaceuticals annual total liabilities is currently $235.21 million, with the most recent change of +$70.03 million (+42.40%) on 31 December 2023. During the last 3 years, it has risen by +$188.19 million (+400.19%). MDGL annual total liabilities is now at all-time high.MDGL Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$296.11 M
+$53.44 M+22.02%
30 September 2024
Summary:
Madrigal Pharmaceuticals quarterly total liabilities is currently $296.11 million, with the most recent change of +$53.44 million (+22.02%) on 30 September 2024. Over the past year, it has increased by +$80.39 million (+37.27%). MDGL quarterly total liabilities is now at all-time high.MDGL Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +42.4% | +37.3% |
| 3 y3 years | +400.2% | +324.1% |
| 5 y5 years | +2685.6% | +1761.7% |
MDGL Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +400.2% | at high | +324.1% |
| 5 y | 5 years | at high | +2685.6% | at high | +1761.7% |
| alltime | all time | at high | >+9999.0% | at high | +8702.3% |
Madrigal Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $296.11 M(+22.0%) |
| June 2024 | - | $242.67 M(+4.8%) |
| Mar 2024 | - | $231.52 M(-1.6%) |
| Dec 2023 | $235.21 M(+42.4%) | $235.21 M(+9.0%) |
| Sept 2023 | - | $215.72 M(+8.4%) |
| June 2023 | - | $198.96 M(+9.1%) |
| Mar 2023 | - | $182.31 M(+10.4%) |
| Dec 2022 | $165.18 M(+113.9%) | $165.18 M(+11.6%) |
| Sept 2022 | - | $147.97 M(+11.4%) |
| June 2022 | - | $132.86 M(+72.7%) |
| Mar 2022 | - | $76.92 M(-0.4%) |
| Dec 2021 | $77.22 M(+64.2%) | $77.22 M(+10.6%) |
| Sept 2021 | - | $69.82 M(+21.8%) |
| June 2021 | - | $57.30 M(+16.5%) |
| Mar 2021 | - | $49.18 M(+4.6%) |
| Dec 2020 | $47.02 M(+84.5%) | $47.02 M(-5.8%) |
| Sept 2020 | - | $49.91 M(+9.8%) |
| June 2020 | - | $45.47 M(+75.0%) |
| Mar 2020 | - | $25.98 M(+1.9%) |
| Dec 2019 | $25.49 M(+201.9%) | $25.49 M(+60.3%) |
| Sept 2019 | - | $15.90 M(+23.9%) |
| June 2019 | - | $12.84 M(+16.1%) |
| Mar 2019 | - | $11.05 M(+30.9%) |
| Dec 2018 | $8.44 M(-16.0%) | $8.44 M(+27.1%) |
| Sept 2018 | - | $6.64 M(+22.2%) |
| June 2018 | - | $5.44 M(-13.6%) |
| Mar 2018 | - | $6.29 M(-37.4%) |
| Dec 2017 | $10.05 M(+109.5%) | $10.05 M(+18.0%) |
| Sept 2017 | - | $8.52 M(+32.4%) |
| June 2017 | - | $6.44 M(+9.0%) |
| Mar 2017 | - | $5.91 M(+23.0%) |
| Dec 2016 | $4.80 M(-90.3%) | $4.80 M(+22.6%) |
| Sept 2016 | - | $3.92 M(+16.4%) |
| June 2016 | - | $3.36 M(-61.1%) |
| Mar 2016 | - | $8.64 M(-82.5%) |
| Dec 2015 | $49.28 M(+38.7%) | $49.28 M(+60.8%) |
| Sept 2015 | - | $30.64 M(-5.9%) |
| June 2015 | - | $32.56 M(-2.1%) |
| Mar 2015 | - | $33.25 M(-6.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $35.54 M(-22.9%) | $35.54 M(-11.0%) |
| Sept 2014 | - | $39.93 M(-4.8%) |
| June 2014 | - | $41.95 M(-4.6%) |
| Mar 2014 | - | $43.96 M(-4.7%) |
| Dec 2013 | $46.11 M(+65.0%) | $46.11 M(+9.7%) |
| Sept 2013 | - | $42.05 M(+9.3%) |
| June 2013 | - | $38.49 M(+3.8%) |
| Mar 2013 | - | $37.10 M(+32.7%) |
| Dec 2012 | $27.95 M(+1.5%) | $27.95 M(+9.9%) |
| Sept 2012 | - | $25.42 M(-4.8%) |
| June 2012 | - | $26.70 M(+2.4%) |
| Mar 2012 | - | $26.07 M(-5.4%) |
| Dec 2011 | $27.55 M(-9.9%) | $27.55 M(-5.9%) |
| Sept 2011 | - | $29.29 M(+0.4%) |
| June 2011 | - | $29.18 M(-2.1%) |
| Mar 2011 | - | $29.82 M(-2.5%) |
| Dec 2010 | $30.59 M(+27.5%) | $30.59 M(-3.3%) |
| Sept 2010 | - | $31.62 M(+85.7%) |
| June 2010 | - | $17.03 M(-11.1%) |
| Mar 2010 | - | $19.15 M(-20.2%) |
| Dec 2009 | $24.00 M(-84.6%) | $24.00 M(-10.2%) |
| Sept 2009 | - | $26.73 M(-83.0%) |
| June 2009 | - | $156.77 M(-9.3%) |
| Mar 2009 | - | $172.88 M(+10.8%) |
| Dec 2008 | $156.04 M(+59.6%) | $156.04 M(+24.5%) |
| Sept 2008 | - | $125.37 M(+28.9%) |
| June 2008 | - | $97.27 M(+1.4%) |
| Mar 2008 | - | $95.92 M(-1.9%) |
| Dec 2007 | $97.75 M(+72.9%) | $97.75 M(+477.0%) |
| Sept 2007 | - | $16.94 M(-11.5%) |
| June 2007 | - | $19.14 M(+22.2%) |
| Mar 2007 | - | $15.66 M(-72.3%) |
| Dec 2006 | $56.54 M(+201.8%) | $56.54 M(+1.0%) |
| Sept 2006 | - | $55.99 M(+198.9%) |
| Dec 2005 | $18.73 M(+33.2%) | $18.73 M(+7.6%) |
| Mar 2005 | - | $17.41 M |
| Dec 2004 | $14.06 M(+302.3%) | - |
| Dec 2003 | $3.50 M(>+9900.0%) | - |
| Dec 2001 | $29.00 K | - |
FAQ
- What is Madrigal Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual total liabilities year-on-year change?
- What is Madrigal Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly total liabilities year-on-year change?
What is Madrigal Pharmaceuticals annual total liabilities?
The current annual total liabilities of MDGL is $235.21 M
What is the all time high annual total liabilities for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual total liabilities is $235.21 M
What is Madrigal Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, MDGL annual total liabilities has changed by +$70.03 M (+42.40%)
What is Madrigal Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of MDGL is $296.11 M
What is the all time high quarterly total liabilities for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly total liabilities is $296.11 M
What is Madrigal Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, MDGL quarterly total liabilities has changed by +$80.39 M (+37.27%)